Literature DB >> 10744051

Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.

Y Ishikawa1, T Kubota, Y Otani, M Watanabe, T Teramoto, K Kumai, T Takechi, H Okabe, M Fukushima, M Kitajima.   

Abstract

We investigated the correlation between tumor sensitivity to 5-fluorouracil (5-FU) and enzymatic activities of thymidylate synthetase (TS) and dihydropyrimidine dehydrogenase (DPD) in human gastric cancer specimens. Forty-one patients with advanced gastric cancer gave informed consent and were enrolled in the study. Biopsy specimens of gastric cancer were obtained preoperatively through gastrofiberscopy and used to determine TS and DPD messenger RNA (mRNA) levels. TS and DPD enzyme activity and mRNA levels were also measured in resected tumor tissue samples obtained after surgical resection. TS and DPD activity were measured using the TS-binding assay and a radioenzymatic assay, respectively, while mRNA levels were measured by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR), with co-amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal standard. 5-FU sensitivity of resected tumor specimens was measured by the tetrazolium-based colorimetric assay (MTT assay). Both TS and DPD mRNA levels correlated well between biopsied and resected tumor specimens. A statistically significant correlation was also observed between mRNA levels in biopsied specimens and enzymatic activities in resected specimens. DPD levels significantly correlated with 5-FU sensitivity, such that high DPD activity and high DPD mRNA levels resulted in low sensitivity to 5-FU. In contrast, no correlation was observed between TS activity or TS mRNA levels and 5-FU sensitivity. We conclude that tumor DPD mRNA level, as assessed from biopsy specimens obtained by gastrofiberscopy, may be a useful indicator in predicting tumor sensitivity to 5-FU in patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744051      PMCID: PMC5926227          DOI: 10.1111/j.1349-7006.2000.tb00866.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


5‐fluorouracil 5‐fluoro‐dUMP thymidylate synthetase dihydropyrimidine dehydrogenase 2‐mercaptoethanol reverse transcriptionpolymerase chain reaction glyceraldehyde‐3‐phosphate dehydrogenase 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐2H tetrazolium bromide fetal calf serum nicotinamide adenine dinucleotide phosphate
  29 in total

1.  Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate.

Authors:  R J Langenbach; P V Danenberg; C Heidelberger
Journal:  Biochem Biophys Res Commun       Date:  1972-09-26       Impact factor: 3.575

2.  5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice.

Authors:  T Inada; A Ichikawa; T Kubota; Y Ogata; A R Moossa; R M Hoffman
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

Review 3.  Chemotherapy of gastric cancer.

Authors:  D L Schipper; D J Wagener
Journal:  Anticancer Drugs       Date:  1996-02       Impact factor: 2.248

4.  Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.

Authors:  Y Ishikawa; T Kubota; Y Otani; M Watanabe; T Teramoto; K Kumai; T Takechi; H Okabe; M Fukushima; M Kitajima
Journal:  Anticancer Res       Date:  1999 Nov-Dec       Impact factor: 2.480

5.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

Authors:  C G Leichman; H J Lenz; L Leichman; K Danenberg; J Baranda; S Groshen; W Boswell; R Metzger; M Tan; P V Danenberg
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

6.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

7.  Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.

Authors:  C Aschele; A Sobrero; M A Faderan; J R Bertino
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

8.  Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.

Authors:  G J Peters; C L van der Wilt; C J van Groeningen; K Smid; S Meijer; H M Pinedo
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

9.  MTT assay with reference to the clinical effect of chemotherapy.

Authors:  A Suto; T Kubota; Y Shimoyama; K Ishibiki; O Abe
Journal:  J Surg Oncol       Date:  1989-09       Impact factor: 3.454

10.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.

Authors:  A Beck; M C Etienne; S Chéradame; J L Fischel; P Formento; N Renée; G Milano
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

View more
  26 in total

Review 1.  Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question.

Authors:  Tetsuro Kubota; Larry Weisenthal
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

2.  Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.

Authors:  Jin Ho Baek; Jong Gwang Kim; Shi Nae Kim; Dong Hwan Kim; Sang Kyun Sohn; Young Jun Hong; Kyu Bo Lee
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

3.  Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.

Authors:  Osamu Kikuchi; Shinya Ohashi; Yukie Nakai; Shunsaku Nakagawa; Kazuaki Matsuoka; Takashi Kobunai; Teiji Takechi; Yusuke Amanuma; Masahiro Yoshioka; Tomomi Ida; Yoshihiro Yamamoto; Yasushi Okuno; Shin'ichi Miyamoto; Hiroshi Nakagawa; Kazuo Matsubara; Tsutomu Chiba; Manabu Muto
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 4.  Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

Authors:  Wataru Ichikawa
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

5.  Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.

Authors:  Shigeki Nakayama; Shin Takeda; Yoshihisa Kawase; Soichiro Inoue; Tetsuya Kaneko; Akimasa Nakao
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

6.  Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.

Authors:  T Elraiyah; C R Jerde; S Shrestha; R Wu; Q Nie; N H Giama; V Sarangi; L R Roberts; S M Offer; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2016-11-26       Impact factor: 6.875

Review 7.  Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.

Authors:  Marwa Matboli; Sarah El-Nakeep; Nourhan Hossam; Alaa Habieb; Ahmed E M Azazy; Ali E Ebrahim; Ziad Nagy; Omar Abdel-Rahman
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

8.  Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer.

Authors:  Bunzo Nakata; Kazuya Muguruma; Shigehito Yamagata; Kiyotaka Yukimoto; Kiyoshi Maeda; Yukio Nishiguchi; Masaichi Ohira; Yasuyuki Kato; Kosei Hirakawa
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

9.  Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.

Authors:  Tao Ma; Zheng-Gang Zhu; Yu-Bao Ji; Yi Zhang; Ying-Yan Yu; Bing-Ya Liu; Hao-Ran Yin; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

10.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.